Private Care SPRING 2021
GIANT LEAPS
How new treatments are giving hope to skin and kidney cancer patients Why The Royal Marsden is like no other: three patients tell their stories
SPRING 2021
RESEARCH AT THE ROYAL MARSDEN
THE FACTS
£15m
in research funding over five years was granted by The Royal Marsden Cancer Charity in 2016
WELCOME As the Managing Director of Private Care at The Royal Marsden, I’m pleased to introduce the latest issue of Private Care magazine. Despite the ongoing COVID-19 pandemic, we remain open for business and are continuing to deliver treatment and care safely. In this issue, we reveal more about our new diagnostics and treatment centre in Cavendish Square, including the different facilities and treatment options that will be available when it opens later this year. We also look at the latest research being carried out at The Royal Marsden, including the use of artificial intelligence in lung cancer, and genetic testing to determine a man’s increased risk of prostate cancer. The front cover of this magazine features Professor James Larkin, one of our leading melanoma and kidney cancer specialists. He will be one of the oncologists with clinics at Cavendish Square, offering the latest in research-based diagnosis and treatment for patients. Read more about the work he has done to date and what he sees as the future for these diseases in our Consultant Focus feature. I hope you enjoy this issue. Shams Maladwala Managing Director of Private Care ON THE COVER Professor James Larkin, Consultant Medical Oncologist
2 Private Care magazine
6
studies of the impact of COVID-19 on cancer treatment are taking place at The Royal Marsden
75
early-phase trials are conducted by the Oak Foundation Drug Development Unit every year
750
clinical trials involving The Royal Marsden are running at any one time
45%
of our young patients are involved in clinical trials
FIND OUT MORE
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
Some of the photographs in this issue were taken prior to the COVID-19 pandemic and may not reflect current social distancing and PPE guidelines
U P DAT E
SHORTER SESSIONS Jennifer Webster (right) was one of the first patients to be treated on our new CyberKnife (below)
NEW CYBERKNIFE GETS TO WORK THE FIRST PATIENTS have been treated on The Royal Marsden’s new CyberKnife machine in Sutton – the only one of its kind in the UK. Funded by The Royal Marsden Cancer Charity,
CyberKnife can deliver radiotherapy with pinpoint accuracy in sessions as short as 15 minutes, meaning less healthy tissue is damaged during treatment and fewer treatment sessions are needed.
Following a period of remission from bowel cancer, Jennifer Webster, 39, was treated on the new CyberKnife after discovering that her cancer had come back and travelled to her brain. She said: “The Private Care team at The Royal Marsden were incredibly welcoming and explained everything really well, so I knew what to expect. The treatment sessions were so much shorter than when I had pelvic radiotherapy previously – that went on for five weeks and I experienced far more short- and long-term side effects. “Having such focused sessions over three days has made a huge difference. The Royal Marsden is a lovely place to be – everyone has been so helpful and friendly.”
TALKING POINTS “The Royal Marsden really is a special place, full of hope and positivity. I feel so lucky to be looked after there” Page 6
“Cavendish Square will offer worldclass cancer care in the heart of London’s most respected healthcare district” Page 8
“The Robotic Surgery Fellowship means that patients across the country will benefit from robotic surgery” Page 12
“The key to treating melanoma and kidney cancer will be in understanding every patient’s disease at an individual level” Page 14
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
3
IN BRIEF Scholar’s story
Florence Nightingale Foundation scholarships offer nurses and midwives opportunities for leadership development. One such scholar is Lian Lee, a Matron at The Royal Marsden, who has shared her story and experience of the scholarship – including her thoughts on leadership throughout the challenges of 2020 – on the foundation’s website. Read her inspiring blog at florencenightingale-foundation.org. uk/news-events
SCREEN TIME Consultant Professor Robin Jones speaks to a patient using Attend Anywhere
High standards
The Royal Marsden has again been awarded the Customer Service Excellence Standard, which recognises organisations whose services are efficient, effective, excellent, equitable and empowering. The Trust was rated as compliant across all elements, with the assessor impressed by our work in response to the pandemic.
Making voices heard
The NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research, London, has launched a new digital platform to enable patients, carers and the public to have their say about improving cancer research and treatment while enabling healthcare professionals to include a wider range of people in their research. Find out more at patients-voice.cancerbrc.org 4 Private Care magazine
CONSULTATIONS IN COMFORT ATTEND ANYWHERE, a new video consultation service, has been launched at The Royal Marsden to allow patients to speak with their consultant from the comfort of their own homes. Following the onset of the COVID-19 pandemic, we have adapted some of the ways we provide healthcare to ensure the safety of patients and staff. Maria Perrin, Private Patient Operations Manager, said: “Virtual consultations are a convenient and efficient
way for patients to speak with their clinical teams. “To date, we’ve had over 1,200 virtual consultations with private patients both in the UK and overseas, with about 60 consultants using the platform across a number of different tumour groups.” Sarah Eze, 50, a private neuro-oncology patient at The Royal Marsden, has benefited from a number of virtual consultations with her consultant Dr Liam Welsh. She said: “I’ve found the virtual consultations
extremely efficient and straightforward. Dr Welsh has even been able to share images from scan results on the screen so we can discuss them. “I’ve enjoyed not having to travel into the hospital unnecessarily, as well as the opportunity to have my husband with me at home when hearing test results.”
“I found the consultations very efficient”
U P DAT E
Genes may hold clues about prostate cancer risk RESEARCHERS AT The Royal Marsden and The Institute of Cancer Research, London, are aiming to find out why men of African or Caribbean descent are more likely to be diagnosed with prostate cancer. Professor Ros Eeles, Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden and Professor of Oncogenetics at the ICR, is leading the PROFILE study. She NEW STUDY Participant Frederick Forster (below); Professor Ros Eeles (below right)
said: “We believe the secret may lie in changes in the DNA passed on through generations and inherited by men from their parents. But the only way to find out is to do a study like this one.” Frederick Forster, a participant in the study, said: “My father was treated at The Royal Marsden and passed away from prostate cancer. I know my family history and ethnic background put me at greater risk of developing prostate cancer, so I want to help the researchers and doctors find out why this is and what can be done about it.”
APPROVAL FOR KIDNEY DRUGS Positive data from the JAVELIN Renal 101 trial – which researchers at The Royal Marsden have contributed to – has led to the approval of a promising new treatment for patients with a type of kidney cancer. NHS patients with advanced renal cell carcinoma can now benefit from the immunotherapy drug avelumab plus axitinib, a targeted therapy. Professor James Larkin, Consultant Medical Oncologist and investigator on the JAVELIN Renal 101 trial, said: “This approval is excellent news and an important advancement for patients. “This is the first time a first-line combination therapy with immunotherapy and targeted therapy has been approved on the NHS for the treatment of metastatic kidney cancer, which will make a real difference to patients and their quality of life.”
Researchers use AI to spot lung cancer sooner Thanks to funding from The Royal Marsden Cancer Charity, the Trust is establishing an Early Diagnosis Centre to support research and specialists in this field. Two clinical oncology registrars are working alongside Dr Richard Lee, Consultant in Early Diagnosis, to investigate how artificial intelligence (AI) technology can
be used to diagnose lung cancer earlier and provide better care and treatment. Dr Benjamin Hunter is developing AI tools to predict whether lung nodules are malignant or benign, and establishing a system to enable NHS trusts across London to collaborate in AI-based lung
cancer research through the LIBRA study. And Dr Sumeet Hindocha is running the multi-centre OCTAPUS-AI study, which aims to use AI to determine the cause of changes in the lung, better predict which patients are at risk of their cancer returning, and detect recurrence earlier.
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
5
WHY THE ROYAL MARSDEN IS LIKE NO OTHER Cancer is a complex disease, requiring first-rate diagnosis, treatment and care – and this is where we lead the way. Here, three patients tell us why they believe The Royal Marsden Private Care is like no other
“The secretaries were so kind and my CNS really put me at ease. They are at the top of their game” Delilah Jeary
Breast cancer patient
6 Private Care magazine
“I was diagnosed with invasive lobular carcinoma, a type of breast cancer, in November 2017. I spoke to friends and family, and many people suggested that I should go to The Royal Marsden to see Mr Gerald Gui, a Consultant Breast Surgeon. “The secretaries were so kind and helpful. I felt like I was going
to see the very best in London. My Clinical Nurse Specialist, Sarah Irving, was lovely and really put me at ease. You just feel like the staff are at the top of their game. There’s something incredibly comforting about being in a place where you know you’re surrounded by world-leading experts.”
PAT I E N T P E R S P E C T I V E S
“The Royal Marsden is a research-led institution... When they proposed a new immunotherapy treatment, I felt I could really trust them” Alex Green
Melanoma patient
“I was initially diagnosed with melanoma in 2012. I underwent a short course of surgery to remove the tumour, and thought that was that. Unfortunately for me, it turned out the melanoma had spread into the lymph nodes of my neck and the back of my head. At that point, I was a late-stage melanoma patient. “The Royal Marsden is a research-led institution, which really influenced my decision to be treated
there. My family and I did a lot of research, but The Royal Marsden’s name kept coming up. I was referred to Professor James Larkin and underwent several operations to remove tumours, as well as a course of post-surgery radiotherapy. “Throughout my treatment journey, Professor Larkin and Nikki Hunter, my Clinical Nurse Specialist, were fantastic and really supported me and my family. When they proposed a new immunotherapy treatment – which had become available following clinical trials that Professor Larkin and The Royal Marsden had been at the forefront of – I felt I could trust their advice and that they would do their best for me. At my scans in June 2017, there was no trace of cancer anywhere. “The Royal Marsden really is a special place, full of hope and positivity. I feel so lucky to be looked after there.”
“The healthcare professionals at The Royal Marsden have been, and continue to be, amazing. My team were so reassuring” Chris Lee
Sarcoma patient “In March 2017, I was diagnosed with a gastrointestinal stromal tumour, a rare type of sarcoma found in the digestive system. I was referred to The Royal Marsden, where specialists carried out further tests. I was then treated with targeted drugs to shrink the tumour, which was removed by surgeons that December.
“The healthcare professionals at The Royal Marsden have been, and continue to be, amazing. When you’re diagnosed with cancer, your life flashes forwards so quickly and you think, ‘This might be the end of my life.’ Yet I felt at ease as my healthcare team were so reassuring.
“My experience at The Royal Marsden has been absolutely fantastic. Without the research it does and the treatment it provides, I probably wouldn’t be here now.”
FIND OUT MORE
Visit royalmarsden.nhs.uk/ royal-marsden-like-no-other
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
7
WORLD-CLASS CANCER CARE IN THE HEART OF LONDON 8 Private Care magazine
O U T S TA N D I N G FA C I L I T I E S
GRAND DESIGN The location of the new centre in Cavendish Square
Our new centre in Cavendish Square will give private outpatients access to expert consultants and leading-edge equipment in a state-of-the-art setting
Photograph: Alamy
THIS SPRING, The Royal Marsden Private Care is expanding its presence in London by opening a new COVID-secure diagnostic and treatment facility in Cavendish Square. The new outpatients centre – located in the capital’s renowned healthcare district, between Oxford Street and Harley Street – will offer patients fast and direct access to world-leading diagnostic experts in a modern and reassuring environment. At the centre, experts will treat multiple tumour types – including breast, urological, gynaecological, gastrointestinal, head and neck, haematological and skin cancers – and offer other specialties such as genetics, plastics and pain management. Patients can expect to have an appointment booked following their initial enquiry, with direct access to diagnostic services. They may also have next-day appointments and same-day scans and results. In addition to consulting rooms, 12 chemotherapy chairs and a minor procedure suite, the new centre will house stateof-the-art imaging facilities, including MRI, ultrasound, computerised tomography (CT), mammography and X-ray.
“Cavendish Square will offer leading expertise, facilities and technology”
The highest standards Professor Christopher Nutting, Consultant Clinical Oncologist at The Royal Marsden and Professor of Radiotherapy at The Institute of Cancer Research, London, will take up the role of Clinical Director of The Royal Marsden Private Care at Cavendish Square. He says: “Cavendish Square is an exciting new development that will allow us to offer word-class standards of cancer care in the heart of London’s most respected healthcare district for the first time. “Patients seeking the very best private cancer treatment can do so in the Harley Street district, safe in the knowledge that it is backed by the strictest safety standards and governance usually only seen in the NHS. As a specialist cancer centre, Cavendish Square will have the clinical expertise, facilities and technology to provide leading diagnostics and treatment, and our multidisciplinary teams will be on hand to offer a personalised approach.” Backed by research Improving patient access to better and more rapid diagnostics is a priority at The Royal Marsden, and Cavendish Square is part of our broader strategy to diagnose cancer faster and earlier. Experts at The Royal Marsden are constantly working to improve the way we diagnose cancer – for example, through genetic sequencing to identify targetable mutations, and regular screenings of those with a genetic predisposition to certain cancers. Armed with the latest technology, our clinicians can also
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
9
O U T S TA N D I N G FA C I L I T I E S
WHAT WE OFFER AT CAVENDISH SQUARE
CLINICAL DIRECTOR Professor Christopher Nutting
carefully monitor patients for the signs of relapse: the earlier clinicians pick up a recurrent cancer, the better the chance of successfully managing it. This research backing really sets Cavendish Square apart. Patients can feel reassured that their treatment and care is based on the latest advances in oncology led by world-leading experts. In addition, The Royal Marsden has a unique integrated model in which all revenue generated from the Private Care service goes back to the NHS Foundation Trust. This provides the best of both worlds for patients and clinicians: NHS scale, specialisms, research and governance delivered with privatesector service standards.
“The onsite diagnostic imaging suite will make a huge difference to patients” 10 Private Care magazine
Speedier diagnosis Dr Susan Lalondrelle is a Consultant Clinical Oncologist specialising in the treatment of gynaecological and skin cancers with radiotherapy, brachytherapy and systemic therapies, and is the Lead for Clinical Oncology at The Royal Marsden. She is one of many consultants who will be providing care in the centre. “We’re delighted that Cavendish Square will be opening soon,” says Dr Lalondrelle. “Having a full diagnostic imaging suite on site will make a huge difference to patients. “Rapid diagnostics will allow us to diagnose cancers earlier. When a patient’s cancer is detected at an early stage, there is a much greater chance of being able to treat it successfully, often with less invasive procedures and fewer long-term side effects. “At The Royal Marsden, we thrive on change, pioneering the latest treatments and using the newest technology for the benefit of our patients. Our radiotherapy studies have changed the way cancer patients are treated – not only here but also across the country and around the world.”
Our services • Fully comprehensive cancer diagnostic and treatment centre with fast and direct access to research-led diagnostic experts covering all main tumour groups and clinical specialties: • Breast • Urology • Head and neck • Gastrointestinal • Gynaecological • Haemato-oncology • Skin • Lung • Genetics • Plastic surgery and reconstruction • Same-day and next-day appointments with our world-leading consultants in surgery, medical oncology, clinical oncology, haematology and genetics • One-stop diagnostic appointments Our facilities • Full diagnostic imaging suite offering MRI, CT, X-ray, mammography and ultrasound, plus nasoendoscopy and colposcopy • Medical oncology treatments in our Medical Day Unit, which features 12 chemotherapy chairs • Seven outpatient consulting rooms • Minor procedure suite • Onsite pathology with rapid blood test turnaround times • Onsite pharmacy
MOLE MAPPING
SAVING YOUR SKIN Our mole-mapping clinic can benefit patients at risk of skin cancer, says Consultant Dermatologist Dr Kara Heelan Q What is mole mapping? A Mole mapping is a surveillance service that aims to monitor the appearance of moles over time and to identify new suspicious lesions or changes in existing lesions. Mole mapping may be offered to patients who are at risk of, or who are concerned about, developing skin cancer. Q How is the service delivered? A It is led and delivered by dermatology consultants at The Royal Marsden in Chelsea and Sutton, and combines a clinical and dermoscopic examination of the skin with total body mapping and digital dermoscopy. We provide patients with copies of their images as this has been shown to increase self-surveillance, which is an important part of ongoing monitoring. Q What does it involve? A We use the FotoFinder Bodystudio Automated Total
Body Mapping machine to take a series of images of the patient’s skin. The separate images are automatically stitched together to create a whole-body map. This is then used to tag close-up digital dermoscopy images of individual suspect lesions. The images are then stored, and all follow-up photos – usually taken at six- to 12-month intervals – are automatically compared with the baseline images. This two-step method means we can detect and diagnose worrisome lesions quickly. In addition, the FotoFinder Moleanalyzer Pro uses artificial intelligence to evaluate and
provide a score for each lesion, which serves as a second opinion. Q How can patients access the service? A Our clinic is different from high street walk-in services, in which patients who don’t meet high-risk criteria may sometimes undergo mole mapping. This may lead to unnecessary excisions and make patients more anxious. By contrast, we only provide the service to patients who are deemed to be high risk and who would potentially benefit from it. These patients can be referred by their GP or consultant for consideration for mole mapping.
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
11
FINE FELLOWS
Mr Ibnauf Suliman Mr Suliman, who was The Royal Marsden’s first robotics fellow, completed his one-year training in April 2018. He is now a Consultant Colorectal and General Surgeon at the Royal Free London specialising in minimally invasive surgery. “I gained experience with three different specialties – urology, gynaecology and coloproctology – which aren’t normally integrated in training,” he says. “It also prepared me to become a consultant. There’s a closeknit community of world-class experts at The Royal Marsden, and learning from them enhanced my leadership and organisational skills.” 12 Private Care magazine
Mr Marc Bullock After completing his Royal Marsden training in April 2019, Mr Bullock became a Consultant Colorectal Surgeon at the Royal United Hospital in Bath and found that the fellowship advanced his career prospects. “Thanks to The Royal Marsden, I’m one of a small number of colorectal surgeons who underwent robotic training before becoming a consultant,” he says. “This was a huge advantage in securing my current job, where I’m planning to set up a surgical robotics programme.”
Ms Danielle Collins Ms Collins, a Consultant Colorectal Surgeon, finished the fellowship in August 2019. She moved to Western General Hospital in Edinburgh, where she pioneered the use of the Versius surgical robot in both the NHS and Europe. She says: “While Versius differs from the da Vinci system, the fellowship gave me a good understanding of how the technology works. I also learned how to perform pelvic exenteration, a complex surgical procedure used when cancer has spread within the pelvis. “Robotic surgery can make operations easier as you can see better, have a greater range of movement and be more precise.”
Photograph of Ms Collins: NHS Lothian
The Royal Marsden launched the Robotic Surgery Fellowship in 2017 with funding from The Royal Marsden Cancer Charity. Since then, we’ve trained six surgeons to operate on patients using the da Vinci surgical robots. We find out how their training has given them the expertise to perform robotic surgery in hospitals in the UK and beyond
R O B OT I C S U R G E RY
Ms Ailín Rogers The most recent robotic recruit, Ms Rogers will complete her training in August. She recently secured a position as a Consultant Colorectal Surgeon at Mater Hospital in Dublin. “Traditionally, surgeons have been trained separately in gynaecology, urology and coloproctology,” she says. “However, pathologies in the pelvis don’t obey these rules, so it’s beneficial to be equipped with the skills to operate in all the pelvic compartments. “I’m excited by the possibilities, including expanding my skill set and using robotic surgery in more advanced cancer cases. My main goal is to improve patient experience and outcomes in my next role as consultant surgeon in Ireland.”
OUR ROBOTICS EXPERTISE
Ms Eva Bolton Ms Bolton became a Consultant Uro-oncologist at Imperial College Healthcare NHS Trust after completing her training in August 2020. She says: “The fellowship gave me a great introduction to robotics. I became a surgeon so that I could help people, and the multi-specialty training has improved my overall patient care.”
Miss Manou Kaur After finishing her training in October 2020, Miss Kaur joined Liverpool Women’s Hospital as a Consultant Gynaecological Surgeon to set up a robotic surgical programme to improve the treatment of gynaecological diseases. She says: “The fellowship means that more patients across the country will benefit from the latest robotic surgery.”
Since 2007, The Royal Marsden has performed robotically assisted surgical procedures for patients with various cancer types using the groundbreaking da Vinci robotic surgical system, meaning less pain and a faster recovery following surgery. Today, we have two da Vinci Xi robots in use at the Trust. The Robotic Surgery Fellowship was launched in 2017 to train the robotic surgeons of the future. It is made possible by the da Vinci Xi’s dual console, which allows our consultants to supervise trainees during live surgery without compromising patient safety.
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
13
PROFESSOR JAMES LARKIN Consultant Medical Oncologist
PROFESSOR JAMES LARKIN is a Consultant Medical Oncologist in The Royal Marsden’s Skin and Urology units, and is the Chief Clinical Investigator of translational studies into melanoma and kidney cancer. As a centre of excellence with an international reputation for groundbreaking research in melanoma and in pioneering new treatments for the disease, we collaborate with our academic partner The Institute of Cancer Research, London (ICR), and other respected organisations. Professor Larkin’s research interests involve trying to better understand cancer and its consequences, as well as developing improved
treatments, particularly targeted therapies and immunotherapies. Professor Larkin is Vice Chair of the Cancer Research UK Clinical Research Committee and Lead of the Uncommon Cancers theme at The Royal Marsden and ICR’s Biomedical Research Centre. In 2018, he was elected as a Fellow of the Academy of Medical Sciences. Since 2019, Professor Larkin has been Vice Chair of the Medical Oncology Specialist Advisory Committee for the Joint Royal Colleges of Physicians Training Board, and in 2020 was appointed as a Senior Investigator for the National Institute for Health Research.
CAREER HIGHLIGHTS 1993 Graduates in Natural Sciences from the University of Cambridge 1996 Graduates in Clinical Medicine from the University of Oxford 2000 Joins The Royal Marsden as Professor Martin Gore’s senior house officer 14 Private Care magazine
Q&A 2001 Completes MRC Clinical Research Training Fellowship 2004 Receives PhD at the ICR 2018 Appointed Professor by the ICR 2018 Elected Fellow of the Academy of Medical Sciences 2020 Appointed as NIHR Senior Investigator
Q How has the treatment of melanoma and kidney cancer changed during your career? A When I started as a consultant in 2008, both diseases were generally regarded as untreatable once they’d spread. With drug treatment, the average life expectancy was less than a year. In the past 15 years, drugs have been developed that will
C O N S U LTA N T F O C U S
“The greatest advances in the treatment of melanoma and kidney cancer in the past five years have been in the field of immunotherapy” their disease and recommend the best approach to treatment. Q What services will you be providing at the new private outpatients centre in Cavendish Square? A The focus there will be on diagnostics as well as treatment. I’ll be running initial assessment consultations and outpatient clinics in both melanoma and kidney cancer. Same-day blood and radiology diagnostic tests will be available, as well as onsite treatments including immunotherapy and targeted therapies.
help to control the disease in many people and probably lead to cure in a proportion of people with metastatic melanoma and kidney cancer. This progress is a consequence of pioneering research and clinical trials, but there is still more to do. Q What services do you provide at The Royal Marsden? A I see patients with the diagnosis of either melanoma or kidney cancer. I provide a comprehensive evaluation of
Q What areas of research are you involved in? A I’m involved in developing new treatments for melanoma and kidney cancer – and the greatest advances in the past five years have been in the field of immunotherapy. The new generation of drugs – so-called immune checkpoint inhibitors – are now licensed for the treatment of both diseases. They are not effective in all patients, so trials are exploring combining immunotherapy with other types of treatments, as well as cellular therapies and vaccine approaches. Q What does the future hold for the treatment of these cancers? A The key will be in
understanding every patient’s disease at an individual level, and being able to predict its course and the likelihood of specific treatment being effective. There are also questions about the correct sequence and combination of different therapies and their side effects. At the heart of these challenges are questions that concern cancer biology, which will only be answered through continued research. This is led in the Renal and Melanoma units by Dr Samra Turajlic, a Consultant Medical Oncologist and clinician scientist working between The Royal Marsden and the Francis Crick Institute. A key focus is on those patients who don’t benefit from the existing treatments, including those for whom immunotherapy isn’t effective. There is also significant work being done in the area of cellular therapy, led by Dr Andrew Furness, a colleague at The Royal Marsden. Q What is special about The Royal Marsden’s service? A The Royal Marsden is at the forefront of oncology research internationally. It integrates the expertise of various specialists, all of whom bring a unique perspective to the discussion of clinical problems and are always mindful of new scientific and clinical developments.
For referrals and enquiries, call 020 7811 8111 or email privatepatients@rmh.nhs.uk
15
As Europe’s largest cancer centre, The Royal Marsden has the expertise, facilities and technology to provide the highest standards of personalised care, and we treat more private patients than any other UK centre. By choosing The Royal Marsden, you are ensuring the best possible treatment and care, at the moment a patient needs it most. Because where a patient goes first really matters.
Life demands excellence
To refer a private patient, contact our Central Referral and Information Line on +44 (0)20 7811 8111 or email privatepatients@rmh.nhs.uk royalmarsden.nhs.uk/private